Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026)

Kamada (KMDA) posted quarterly Net Income towards Common Stockholders of $6.6 million for Q1 2026, down 28.2% year-on-year from $9.3 million in Q1 2025, and up 12.6% on a QoQ basis from $5.9 million in Q4 2025.

Kamada (KMDA) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends

Kamada (KMDA) has reported Net Income towards Common Stockholders for 15 consecutive years, with $6.6 million the latest figure, recorded in Q1 2026.

  • Quarterly Net Income towards Common Stockholders fell 28.2% year-over-year to $6.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $20.0 million (up 38.82% YoY) and the FY2025 annual result came in at $26.7 million, up 119.04% from the prior year.
  • Net Income towards Common Stockholders improved to $6.6 million in Q1 2026 per KMDA's latest filing, from $5.9 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for KMDA reached as high as $9.3 million in Q1 2025 and fell as low as -$1809.0 in Q1 2023.
  • A 5-year average of $3.3 million and a median of $3.2 million in 2023 frame the typical range for Net Income towards Common Stockholders.
  • The largest YoY upside for Net Income towards Common Stockholders was 537066.67% in 2023 against a maximum downside of 100.1% in 2023.
  • Year by year, Net Income towards Common Stockholders stood at $3.2 million in 2022, then surged by 53.68% to $5.0 million in 2023, then slumped by 77.76% to $1.1 million in 2024, then surged by 432.07% to $5.9 million in 2025, then increased by 12.6% to $6.6 million in 2026.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $6.6 million, $5.9 million, and $7.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Haleon 89.28 Bn 87.42 Bn - -
2 Teva Pharmaceutical Industries 35.97 Bn 32.23 Bn 1.97 Bn 370.00 Mn
3 Zoetis 32.42 Bn 30.48 Bn 1.62 Bn 601.00 Mn
4 Takeda Pharmaceutical 27.48 Bn 23.42 Bn 4.39 Bn -2.35 Bn
5 United Therapeutics 22.89 Bn 20.73 Bn 648.10 Mn 274.90 Mn
6 RedHill Biopharma 22.11 Bn 22.11 Bn - -
7 Viatris 20.44 Bn 18.64 Bn 1.16 Bn 176.40 Mn
8 Neurocrine Biosciences 17.76 Bn 16.44 Bn 800.70 Mn 197.90 Mn
9 Elanco Animal Health 12.62 Bn 12.19 Bn 785.00 Mn 57.00 Mn
10 Kamada 399.49 Mn 326.34 Mn 19.12 Mn 6.65 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 6.65 Mn
Dec 31, 2025 5.91 Mn
Sep 30, 2025 7.44 Mn
Jun 30, 2025 6,328.00
Mar 31, 2025 9.26 Mn
Dec 31, 2024 1.11 Mn
Sep 30, 2024 4.03 Mn
Jun 30, 2024 4,552.00
Mar 31, 2024 2.51 Mn
Dec 31, 2023 4.99 Mn
Sep 30, 2023 3.22 Mn
Jun 30, 2023 1.81 Mn
Mar 31, 2023 -1,809.00
Dec 31, 2022 3.25 Mn
Sep 30, 2022 600.00
Jun 30, 2022 3.95 Mn
Mar 31, 2022 1.83 Mn
Dec 31, 2021 -4.82 Mn
Sep 30, 2021 868,000.00
Jun 30, 2021 965,000.00